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Context: Prognosis in patients with neuroendocrine tumors (NETs) is often poor, frequently re-
flecting delayed diagnosis. Hence, accurate and practical NET markers are needed. Cocaine- and
amphetamine-regulated transcript (CART) peptide is a potential novel NET marker.
Design and Participants: Circulating levels of CART peptide and the established NET markers
chromogranin A (CgA) and chromogranin B (CgB) were measured using RIA in 353 patients with
NET (normal renal function) and in controls. Clinical data were collected retrospectively.
Main Outcome Measure(s): The comparative and combined utility of CART, CgA, and CgB for
diagnosis and assessment of disease progression was measured in different NET subtypes.
Results: CgA and CgB in combination improved diagnostic accuracy in patients with gut NETs,
nongastroenteropancreatic NETs, and NETs with an unknown primary origin compared with each
biomarker alone. Measuring CART did not further improve diagnosis in these NET subtypes. For
pancreatic NETs, CgBwas superior to CgA and CART in detecting stable disease (P .007), whereas
CgA and CART in combination were most effective in identifying progressive disease. In phae-
ochromocytomas/paragangliomas (PCC/PGL), CARTwas themost useful biomarker for identifying
stable (P  .001) and progressive (P  .001) disease. Consistent with this, plasma CART decreased
following PCC/PGL tumor resection, remaining low in all patients in remission, but increasing in
those with progressive disease.
Conclusions: CART is a useful marker for identifying progressive pancreatic NETs. CART is superior
to CgA and CgB in detecting stable and progressive PCC/PGLs, andmay have a role as a surveillance
marker for PCC/PGL patients. (J Clin Endocrinol Metab 100: 1520–1528, 2015)
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Neuroendocrine tumors (NETs) are heterogeneous tu-mors arising from cells that exhibit a neuroendo-
crine phenotype (1). These cells store various bioactive
peptides or amines in large, dense-core vesicles and small,
synaptic-like vesicles. Although the incidence ofNETs has
increased significantly over the last 30 years, 5-year sur-
vival remains poor (2, 3). The average delay betweenonset
of symptoms and NET diagnosis is 5–7 years, resulting in
almost half of patients presentingwith distant metastases.
Even in well-differentiated tumors, patients with distant
metastases have poor survival (4).
The delay in NET diagnosis is partly due to the non-
specific presentation of these tumors, but is compounded
by the lack of early diagnostic biomarkers. The chromo-
granins are the main soluble proteins within the large,
dense-core vesicles, and can be used as markers of neu-
roendocrine cells (5). Although chromogranin A (CgA) is
the most widely used circulating NET biomarker, it is rel-
atively insensitive in identifying early disease (6). Speci-
ficity can also be compromised because circulating CgA
levels can be increased in a number of conditions other
than NETs (7–10). Furthermore, extensive post-transla-
tional modificationmakes CgA assay standardization dif-
ficult (11). Chromogranin B (CgB) may be used in con-
junction with CgA to improve diagnostic accuracy.
Circulating levels of CgB are much less affected by renal
failure thanCgA (12), although the overall diagnostic sen-
sitivity of CgB as a NET marker is considerably poorer
than that of CgA (13).
AlthoughCgAhas been reported to predict disease pro-
gression in advanced pancreatic NETs (14), additional
studies of the currently available circulatingNETmarkers
for specific NET subtypes are needed. Recommended
grading systems for NETs are based on the mitotic rate or
percentage of neoplastic cells, which are immunopositive
for the proliferation marker Ki67 (Ki67 index) (15, 16).
However, suchmeasurements areoftenbasedonrelatively
small biopsy samples and are not always reflective of the
intratumoral heterogeneity that may be present in NETs
(17, 18).
Hence, the development of robust circulatingNETbio-
markers for diagnosis, and to predict disease progression,
would facilitate early tumor detection and targeted man-
agement (19, 20). A preliminary study showed that pa-
tients with a NET had higher plasma cocaine- and am-
phetamine-regulated transcript (CART) peptide levels
thanhealthy controls (21).CARTwas first identified as an
mRNA transcript up-regulated by cocaine and amphet-
amine in the rat brain (22). Since then, CART peptide has
been shown to be widely expressed in neurons and neu-
roendocrine cells in tissues including the pituitary, adrenal
medulla, gut, and pancreas (22). In addition to normal
neuroendocrine cells, CARTpeptide has been shown to be
expressed in NETs including pheochromocytomas (PCC)
(23), glucagonomas (24) and insulinomas (25, 26). How-
ever, the utility of CART as a circulating NET biomarker
has not been assessed.
We evaluated the utility of CART, in comparison with
CgA and CgB, as a diagnostic marker in NETs, and in
specific NET subtypes, and investigated whether CART
can differentiate between stable and progressive disease.
Our results suggest that CART is a useful marker for the
diagnosis andassessmentof tumorbehavior inprogressive
pancreatic NETs and pheochromocytomas/paraganglio-
mas (PCC/PGL).
Materials and Methods
Collection of samples
Local ethical approval was obtained and all participants gave
informed consent. Control samples (n  40) were taken from
healthy volunteersworking at Imperial CollegeHealthcareNHS
Trust, all with normal renal function and not taking any medi-
cations. A single nonfasting 5-mL blood sample was taken from
each participant and collected into K3 EDTA Vacutainer tubes
(Becton, Dickinson, NJ). Samples were centrifuged at 1200 g
for 10 minutes within 15 minutes of collection. Aliquots of
plasmawere stored at20°C until theywere assayed in batches.
The ImperialCollegeHealthcareNHSTrustNeuroendocrine
Tumor Supra-regional Assay Service (SAS) receives samples for
routine clinical analysis from two European Neuroendocrine
Tumor Society (ENETS) Centers of Excellence in London: Im-
perialCollegeHealthcareNHSTrust and theRoyal FreeLondon
NHS Foundation Trust. Following ethical approval, plasma
CART,CgA, andCgBweremeasured in 481 spare aliquots from
confirmed NET patient samples received by the SAS from these
two centers. All patient samples for NET biomarker analysis are
routinely collected and stored under the same conditions out-
lined above. Aliquots of plasmawere stored at20°C until they
were assayed in batches.
Data collection
Clinical datawas obtained retrospectively for all 481 patients
frompatient casenotes, andhospital and laboratory information
systems. Information gathered included source of primary tu-
mor, evidence of disease remission, presence of metastases, dis-
ease progression, Ki-67 index, tumor burden, and renal function
including serum creatinine levels and estimated glomerular fil-
tration rate (eGFR). Patientswere excluded fromfurther analysis
if there was evidence of renal impairment (eGFR 60 mL/min/
1.73m2) (12). Patients were classified as having stable or pro-
gressive disease based on radiological assessment, using the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) criteria
(27). Patients were considered to be in remission if there was no
clinical, biochemical, or radiological evidence of residual
disease.
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RIAs
Plasma CgA and CgB were measured using an in-house sen-
sitive and specific RIA used as part of routine clinical service at
the Neuroendocrine Tumor SAS laboratory, Imperial College
Healthcare NHS Trust (11, 21). Plasma CART was measured
using a well-established specific and sensitive in-house RIA (21,
28). Furtherdetails of theassaysare included in theSupplemental
Methods.
Statistics
Plasma CART concentrations in controls and patients with
NET were compared using the nonparametric Kruskal-Wallis
test. The comparative and combined utility of CART, CgA, and
CgB (for NET diagnosis and for distinguishing between stable
and progressive disease) in different NET subtypes was assessed
usingmultiple logistic regression analysis. Least-significant vari-
ables were omitted from the model using a backwards selection
procedure. The odds ratio, defined as the increase in probability
of having a NET with one-unit increase in log values, was also
calculated.Decision cut-offs for plasmaCART,CgA, andCgB to
calculate sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV) were calculated using re-
ceiver operator characteristic (ROC) curve analysis (31). PPV
andNPVwere adjusted for NET prevalence (32). PlasmaCART
concentrations in patientswith a secretory or nonsecretory PCC/
PGL, and in PCC/PGL patients with and without SDHx muta-
tions, were compared using the Mann-Whitney U test.
Results
Plasma CART as a diagnostic marker for NETs
Plasma CART was measured in 481 patients with a
NET(age range19–101y;medianage, 60y;malen242;
female n  239). Of these 481 patients with NET, 353
were not in remission and/or had no evidence of renal
impairment with eGFR at least 60 ml/min/1.73m2) (pan-
creatic, 117; gut, 131; PCC/PGL, 38; nongastroentero-
pancreatic [GEP], 28; unknownprimary, 39). Plasma con-
centrations of CART, CgA, andCgB in eachNET subtype
comparedwith controls (n 40) are shown inTable 1. All
three biomarkers were significantly elevated in NET sub-
types compared with controls with the exception of CgA
in patients with a PCC/PGL.
The diagnostic utility of measuring a combination of
biomarkerswas assessed usingmultiple logistic regression
analysis (Table 2). Measuring CgA in combination with
CgB significantly improved diagnostic accuracy in pa-
tientswith gutNETs andNETswith an unknownprimary
origin. Measuring the peptide CART in addition to CgA
and CgB did not further improve diagnosis in these NET
subtypes. CgB was the best diagnostic marker for pancre-
aticNETs,withnodiagnostic advantage inalsomeasuring
CgA or CART.
CART was the single best diagnostic biomarker for
PCC/PGL (P  .001), with no additional benefit from
measuring either CgA or CgB. Sympathetic PGL, arising
from either the paravertebral axis (base of skull to pelvis)
or the adrenal medulla (PCC), hypersecrete cat-
echolamines andmetanephrines (33). This hypersecretion
can be confirmed by measuring urine or plasma concen-
trations of catecholamines or theirmetabolitesmetaneph-
rines. Measurement of methoxytyramine, the O-methyl-
ated metabolite of dopamine, has been reported to be
particularly useful in the diagnosis of dopamine-produc-
ing, extra-adrenal PGL tumors (34, 35). In contrast, para-
sympathetic PGLs are often nonsecretory, representing a
particular diagnostic challenge (36). Further analysis was
thus carried out to evaluate the utility of CART as a bio-
marker in patients with a nonsecretory PCC/PGL. Values
for urine/plasma catecholamine/metanephrine levels were
available in 33/38 patients. In 26/33 patients, these were
elevated above the reference range and these patients were
identified as having a secretory PCC/PGL. The remaining
seven patients had catecholamine/metanephrine levels
within the reference range and were hence identified as
having nonsecretory tumors. There was no significant dif-
Table 1. Plasma CART, CgA, and CgB Concentrations
in Patients With a NET compared with Healthy Controls
Biomarker
Plasma Concentration,
Median (IQR)
P Value
(Relative to Controls)
Controls (n  40)
CART 51 (36–67) –
CgA 33 (26–41) –
CgB 70 (63–81) –
All NETs (n  353)
CART 84 (54–225) .0001
CgA 65 (42–263) .0001
CgB 125 (84–193) .0001
Pancreatic NETs (n  117)
CART 84 (56–300) .0001
CgA 51 (39–111) .0001
CgB 110 (71–201) .0001
Gut NETs (n  131)
CART 77 (51–140) .0001
CgA 107 (52–421) .0001
CgB 128 (89–191) .0001
PCC/PGL (n  38)
CART 114 (65–390) .0001
CgA 43 (32–77) NS
CgB 113 (64–161) .0001
NonGEP NETs (n  28)
CART 124 (54–1000) .0001
CgA 48 (37–348) .0001
CgB 121 (74–220) .0001
NETs with Unknown Primary (n  39)
CART 106 (54–224) .0001
CgA 199 (54–679) .0001
CgB 157 (107–239) .0001
NS, nonsignificant.
P  .05 was considered significant. All plasma concentrations are in
pmol/L. Comparisons between groups were made using the Kruskal-
Wallis test.
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ference between plasma CART concentrations in patients
with secretory tumors compared with nonsecretory PCC/
PGL; plasmaCARTmedian interquartile range (IQR)was
130 [63–325] pmol/L vs 108 [56–404] pmol/L for secrete-
tory vs nonsecretory. The sensitivity of each biomarker
compared with the current reference standard of elevated
catecholamines/metanephrines for diagnosis of a secre-
tory PCC/PGL tumorwas: 73.1% (CART), 53.8% (CgA),
and 53.8% (CgB).
A recent study has described a specific role for CgA in
the diagnosis of PCC/PGL in patients with a mutation in
genes encoding subunits B and D of the succinate dehy-
drogenase complex (SDHB/SDHD) (37). Patients with an
SDHB/SDHD mutation and a secretory PCC/PGL often
secretes catecholamines at lower rates compared with pa-
tients with a sporadic PCC/PGL (38). Hence, this relative
biochemical inactivity may delay diagnosis and can make
surveillance difficult. In the current study, 26 patients had
a confirmed secretory PCC/PGL and an SDHxmutation:
SDHB mutation n  8, SDHD mutation n  3. In this
small subset of patients, CART levels were similar in pa-
tients with secretory PCC/PGL tumors with and without
SDHB/SDHDmutations (plasma CART: 114 79–828
[SDHx mutation–positive] (n  11) vs 81  53–192
pmol/L [SDHx mutation–negative] (n  7). Further de-
tails regarding catecholamine/metanephrine secretion in
secretory tumors and mutation analysis are provided in
Supplemental Results.
Supplemental Table 1 shows specificity, sensitivity,
PPV, and NPV for CART, CgA, and CgB in NET diag-
nosis, adjusting for NET prevalence (32).
Plasma CART as a marker for NET disease
progression
Regression analysis was used to investigate circulating
CART, CgA, and CgB as markers of disease progression
(Table 3). The three biomarkers in combination produced
the greatest area under the curve (AUC) for identifying
progressive disease in patients with pancreatic NETs, a
NETof unknownorigin, and aPCC/PGL. In the latter two
groups, plasmaCARTwas the single best biomarker,with
no additional benefit frommeasuringCgAorCgB. In con-
trast, measuring a combination of CgA and CART im-
proved the identification of patients with progressive pan-
creatic NETs. Similar to biomarker performance in NET
diagnosis, sensitivity, specificity, PPV, and NPV were
comparable for all three biomarkers in distinguishing sta-
ble and progressive disease (Supplemental Table 2).
The Ki67 proliferative index is an accepted marker for
staging ofNETs and can be used to predictNETprognosis
(15, 39). Ki67 index was available in 162 patients with
NETs (median, interquartile range: 5%, 2–15%). In these
patients, circulating CART and CgB levels were signifi-
cantly correlatedwith theKi67 index (CgBP .02;CART
P  .05), but circulating CgA levels were not.
Table 2. Comparison of CART, CgA, and CgB as
Diagnostic Markers in Patients With a NET
Biomarker OR (95% CI)
P
Value AUC (95% CI)
Controls (n  40) vs all NETs (n  353)a
CART 1.58 (0.64–3.94) .32 0.83 (0.79–0.88)
CgA 12.2 (2.73–54.3) .001
CgB 10.6 (1.46–77.8) .02
Reduced model using the most significant markersb
CgA 12.1 (2.72–53.9) .001 0.83 (0.79–0.88)
CgB 15.6 (2.46–98.3) .004
Controls (n  40) vs Pancreatic NETs (n  117)a
CART 1.61 (0.97–2.68) .07 0.78 (0.71–0.85)
CgA 1.81 (0.79–4.14) .16
CgB 2.47 (1.28–4.75) .007
Reduced model using the most significant markersb
CgB 61.3 (5.86–641) .001 0.77 (0.70–0.84)
CART 3.39 (1.16–9.93) .03
Controls (n  40) vs Gut NETs (n  131)a
CART 0.22 (0.05–1.08) .07 0.90 (0.85–0.95)
CgA 271 (15.9–4617) .001
CgB 6.76 (2.26–20.2) .001
Reduced model using the most significant markersb
CgA 250 (15.2–4127) .001 0.90 (0.85–0.95)
CgB 19.2 (2.85–129) .002
Controls (n  40) vs Non-GEP NETs (n  28)a
CART 0.96 (0.08–12.2) .98 0.81 (0.70–0.93)
CgA 12.1 (0.69–213) .09
CgB 108 (0.44–26 354) .10
Reduced model using the most significant markersb
CgA 12.0 (0.78–182) .07 0.82 (0.70–0.93)
CgB 104 (0.75–14 412) .07
Controls (n  40) vs PCC/PGL (n  38)a
CART 26.7 (2.64–270) .005 0.71 (0.58–0.84)
CgA 1.34 (0.07–25.1) .84
CgB 3.51 (0.10–120) .49
Reduced model using the most significant markersb
CART 340 (43.2–2682) .001 0.83 (0.75–0.90)
Controls (n  40) vs NETs with unknown primary (n  39)a
CART 531 (4.47–63 004) .10 0.96 (0.91–1.00)
CgA 52.5 (3.88–710) .01
CgB 17.5 (0.56–551) .003
Reduced model using the most significant markersb
CgA 263 (3.40–20 384) .01 0.94 (0.88–1.00)
CgB 40.8 (3.82–435) .002
CI, confidence interval; non-GEP, nongastroenteropancreatic.
Multiple regression analysis including all three biomarkers was carried
out first, followed by a backward selection procedure omitting the
least significant biomarker from the model, before repeating the
regression analysis. P  .05 was considered significant. OR is the
increase in odds of having a NET with a one log-scale unit increase in
concentration of the biomarker.
a The combined area under ROC curve using all three biomarkers.
b AUC when most significant biomarkers are included.
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Plasma CART as a surveillance marker for NETs
Most patients with aNET remain under long-term sur-
veillance, even those who have undergone complete re-
section of their tumor, as recurrence is common.We com-
pared theutility ofCART,CgA, andCgB indifferentiating
patients with a NET in remission from those with active
disease. All three biomarkers were significantly lower in
patients in remission (n  56) compared with those with
active disease (n  353) (ROC AUC, SE [95% CI] for
CART: 0.74, 0.04 (0.70–0.79) (P  .0001); CgA: 0.72,
0.04 (0.67–0.76) (P .0001); andCgB: 0.79, 0.03 (0.74–
0.83) (P  .0001). There was no significant difference
between the AUCs for the three biomarkers.
Plasma CART was the most useful marker for identi-
fying stable orprogressivePCC/PGL.Hence,wemeasured
plasmaCARTconcentrationspreoperatively and forup to
12 months postoperatively in seven PCC/PGL patients
who had undergone surgical resection andwere in clinical
remission, and in two patients with progressive disease
(Figure 1). Plasma CART levels decreased in all patients
who entered clinical remission following surgery, and re-
mained low. In contrast, plasma CART concentrations
increased in the twopatientswithprogressivedisease.This
suggests that CART may be a useful surveillance marker
in patients with a PCC/PGL, although further work is
needed to investigate this as the sample size in this sub-
group analysis was small.
Discussion
Thediverse, oftennonspecificpresentationsand thevaried
clinical course of NETs make their diagnosis and man-
agement challenging. Although CgA is the most widely
Figure 1. Longitudinal study of plasma CART concentrations in
patients with stable and progressive PCC/PGL. Plasma CART was
measured at baseline and at 6–12 months in PCC/PGL patients with
stable (solid lines) and progressive (dashed lines) disease.
Table 3. Comparison of CART, CgA, and CgB in
Identifying Stable and Progressive Disease in Patients
With a NET
Biomarker OR (95% CI)
P
Value AUC (95% CI)
All NETs
(n  349, stable n  239, progressive n  110)a
CART 5.21 (2.82–9.60) .001 0.78 (0.72–0.84)
CgA 1.78 (1.03–3.08) .04
CgB 2.85 (0.78–10.5) .11
Reduced model using the most significant markersb
CgA 2.16 (1.32–3.55) .002 0.78 (0.72–0.83)
CART 6.22 (3.19–11.1) .001
Pancreatic NETs
(n  116, stable n  80, progressive n  36)a
CART 3.30 (1.80–6.08) .001 0.86 (0.79–0.94)
CgA 1.89 (1.07–3.35) .03
CgB 1.20 (0.69–2.06) .52
Reduced model using the most significant markersb
CgA 3.90 (1.40–10.9) .009 0.86 (0.79–0.94)
CART 11.7 (3.81–35.8) .001
Gut NETs
(n  131, stable n  101, progressive n  27)a
CART 1.08 (0.56–2.05) .82 0.69 (0.57–0.81)
CgA 1.10 (0.65–1.87) .71
CgB 2.04 (0.97–4.29) .06
Reduced model using the most significant markersb
CgB 1.63 (1.17–2.27) .004 0.69 (0.57–0.81)
Non-GEP NETs
(n  28, stable n  14, progressive n  14)a
CART 0.85 (0.03–21.1) .92 0.69 (0.47–0.91)
CgA 2.37 (0.16–34.5) .53
CgB 5.63 (0.04–731) .49
Reduced model using the most significant markersb
CgA 3.74 (0.95–14.6) .06 0.71 (0.51–0.92)
PCC/PGL
(n  38, stable n  25, progressive n  13)a
CART 3.24 (0.60–17.3) .17 0.89 (0.78–1.00)
CgA 4.63 (0.47–46.0) .19
CgB 1.02 (0.32–3.22) .97
Reduced model using the most significant markersb
CART 35.3 (4.04–308) .001 0.86 (0.75–0.98)
NETs with unknown primary
(n  39, stable n  19, progressive n  20)a
CART 3.61 (1.22–10.7) .02 0.82 (0.68–0.96)
CgA 2.08 (0.72–6.08) .18
CgB 0.82 (0.25–2.72) .75
Reduced model using the most significant markersb
CART 12.6 (1.94–81.9) .008 0.74 (0.58–0.90)
CI, confidence interval; PCC/PGL,
pheochromocytomas/paragangliomas; non-GEP,
nongastroenteropancreatic.
Multiple regression analysis including all three biomarkers was carried
out first, followed by a backwards selection procedure omitting the
least significant biomarker from the model, before repeating the
regression analysis. P  .05 was considered significant. OR: increase in
odds of having a NET with a one log-scale unit increase in circulating
concentrations of the biomarkers.
a The combined area under ROC curve using all three biomarkers.
b AUC when most significant biomarkers are used.
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used NET biomarker, its utility is limited. There is an ur-
gent need for robust, highly specific diagnostic and prog-
nostic circulating NET biomarkers to enable earlier diag-
nosis and to plan targeted therapy. The peptide CART is
widely distributed throughout the neuroendocrine system
and preliminary studies suggest a role for CART as aNET
marker (12). We have shown that CARTmay have utility
as a circulating NET biomarker to identify progressive
disease, particularly for pancreatic NETs and PCC/PGL
tumors.
Circulating levels of all three biomarkers, CgA, CgB,
and CART, were significantly higher in patients with a
NET compared with healthy controls. Although none of
the markers were sufficiently specific to be used as defin-
itive diagnostic markers for NETs, the ease of sampling
and analysis makes them a useful first-line investigation
for delineating the neuroendocrine etiology of these tu-
mors. Although CgA remained the most useful diagnostic
marker for all NETs, the diagnostic accuracy of each bio-
marker varied with NET subtype. Plasma CART was the
only useful diagnostic biomarker in patients with PCC/
PGL and CgB was the most useful biomarker in patients
with pancreatic NETs. This variation highlights the lim-
itations of using a single biomarker in NET diagnosis and
supports the proposal that biomarkers in combination can
optimize NET diagnosis (13).
We have focused on comparing biomarker perfor-
mance forNETdiagnosis using theodds ratio (OR), rather
than paired indicators. There are several benefits to using
this approach (41). Comparing accuracy using sensitivity
and specificity can be difficult unless one biomarker out-
performs the other in both sensitivity and specificity. In
addition, sensitivity, specificity, PPV, and NPV vary with
the decision cut-off chosen. Furthermore, PPV and NPV
are dependent on the prevalence of the disease in the pop-
ulation in whom the test will be used. PPV will increase
when there is high disease prevalence in the study popu-
lation. The prevalence of NETs in the general population
is 20 in 100 000 (32). However, measurement of these
biomarkers is not performed for general population
screening. Therefore, the prevalence of NETs in the pop-
ulation who will be offered measurement of these bio-
markers due to clinical suspicion of a NET will be higher
than that of the general population, but still significantly
lower than our study population. Without knowing the
prevalence in the clinical population that will have these
biomarkers measured, an accurate prediction of PPV and
NPV is not possible. The calculated PPV for each bio-
marker for NET diagnosis is very low consistent with the
low NET prevalence in the study population.
CgA and CgB are increased in a number of nonneu-
roendocrine disorders, including common conditions
such as heart failure andhypertension (42, 43).Additional
studies are now required to investigate the specificity of
CART as a NET biomarker and to test its utility in the
patient population inwhich itwould be used, for example,
patients with suspected, but not confirmed, NETs. There
are several diagnostic CgA assays, each of which use dif-
ferent antisera, but which do not significantly differ in
their ability to diagnoseNETs (11). All previous reports of
CART as a NET marker have used the same CART RIA
(12, 21). Using this RIA, CART does not display a diurnal
variation or alter with food intake (21), and seems to be
less affected by renal impairment than CgA (12). Similar
to CgA (11), false-positive elevations in CART have been
reported in nonneuroendocrine malignancy (21), which
requires further investigation. A limitation of the current
study is its retrospective design, particularly in terms of
delineating the effects of all thesepotential confounderson
plasma CART. Hence, there is a need for a future pro-
spective study to establish the effects of proton pump in-
hibitor therapy or H2 receptor antagonist therapy on cir-
culatingCART levels, given that the effects of these agents
on CgA and CgB concentrations are well characterized
(42). Similarly, the effects of various therapeutic interven-
tions can influence plasma CgA (44, 45) and hence, po-
tentially plasma CART. Again, due to the retrospective
designof this study, these effects cannot be identifiedusing
the current data. A future prospective study designed to
focus on changes in circulating CART in response to spe-
cific NET treatments such as somatostatin analogs would
be particularly valuable.
Previous reports of the utility of circulating CgA in the
diagnosis of PCC/PGL are conflicting (37, 46–50). Our
data does not support the use of CgA in the diagnosis of
these tumors. Future collaborative studies to further in-
vestigate CgA in PCC/PGL diagnosis could involve CgA
antisera from those centers where a positive role for CgA
has been described (37, 49, 50). Adding plasma CART to
the laboratory biochemical work-up for PCC/PGL diag-
nosis may be particularly valuable. The current study sug-
gests that plasma CART may be elevated in patients with
nonsecretory PCC/PGL tumors, although patient num-
bers are small and a further, larger study is required to
confirm this. If proven to be useful, plasma CART mea-
surement would be invaluable in facilitating earlier detec-
tion of these tumors, particularly in the screening of high-
risk individuals with SDHx mutations, which currently
relies heavily on expensive and time-consuming imaging
studies (51). Although plasma CART was not higher in
patients with secretory PCC/PGL tumors and a mutation
in SDHx, the conclusions from this data are limited, again
by small patient numbers but also by the limited genetic
analysis results available for the PCC/PGL patients re-
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cruited to this study. Future studies of the role of CART in
PCC/PGL diagnosis should include comparison with the
O-methylated dopamine metabolite methoxytyramine in
addition to plasma and urine metanephrines.
CgB provided the greatest diagnostic accuracy for pan-
creatic NETs. An early, small study of the role of CgB in
NET diagnosis also showed high CgB levels in pancreatic
patients with NET (52). Our data suggest that CgA is less
useful inpancreaticNETdiagnosis. Previous reports of the
role of CgA in pancreatic NET diagnosis have been con-
flicting (21, 53–55). This variability emphasizes the need
for a focused panel of NET biomarkers rather than using
a single marker for NET diagnosis, particularly in pan-
creatic NETs.
Recent reports of alternative accurate methods of di-
agnosing NETs may provide interesting opportunities for
future studies to further elucidate the role of CART in
NET diagnosis and in identifying progressive disease.
Duque et al (56) describe a novel biomarker, a multitran-
script molecular signature measured by a serumRT-PCR,
which was superior to CgA in its ability to identify GEP
NETS (57). Previously, neuron-specific enolase, present in
neuronal and neuroendocrine tissue, has been reported as
useful in predicting disease progression and response to
everolimus in patients with advanced pancreatic NETs
(14). The recent CLARINET trial describes CgA as a pre-
dictor of response to the lanreotide in grade 1 or 2 pan-
creatic NETs (45). Pancreastatin, recognized by the CgA
assay used in the current study (11) may have a role in
identifying carcinoid tumors (58), hepatic metastases
from a NET primary (59) and in monitoring response to
hepatic artery chemoembolization (60). It would be par-
ticularly interesting to compare CART with these bio-
markers in exploring response to treatment.
In addition to being useful diagnostic NET markers,
our results suggest that CgA, CgB, and CART can be used
as markers to identify progressive NET disease, with their
utility again depending on the primary NET subtype.
Plasma CART was the single best marker to differentiate
stable from progressive disease in patients with a PCC/
PGL and in those with an unknown primary NET. The
combination of CART and CgA was useful in identifying
patients with a progressive pancreatic NET. This finding
is consistent with previous work suggesting CART acts as
a NET marker (21). It is unclear whether the observed
increase in plasma CART concentrations in patients with
progressive NETs reflects increased secretion from the tu-
mor itself or increased extratumoral secretion in response
to the tumor. The Ki67 index grades the malignant po-
tential of a NET based on its mitotic activity (61). Con-
sistent with a role for CART in predicting NET behavior,
we have shown a strong correlation between circulating
CART and tumor Ki67 index.
In a small, longitudinal cohort of patients with a PCC/
PGL, plasma CART remained low in patients with stable
disease following tumor resection, but increased in pa-
tients with progressive disease. This suggests that plasma
CARTmay also be a useful surveillancemarker in patients
with PCC/PGL. However, larger, long-term longitudinal
studies are needed to assess the utility of CART, alongside
CgA and CgB, in patients with and without SDHx muta-
tions and also in predicting PCC/PGL progression and
outcome.
Another limitation of the current study concerns the
wider relevance of the findings made using our in-house
CART RIA. Comparing the performance of our CART
RIA with that of a commercial CART Enzyme Immuno-
assay confirmed good assay consistency and suggests that
our findings are likely to be applicable to other CART
measurement platforms. However, future studies are re-
quired to formally establish the accuracy and utility of
other CART assays in NET diagnosis and assessment of
disease progression.
In summary, our data suggest that circulating CART is a
useful marker for diagnosis and identifying progressive dis-
ease in patients with a NET. The use of CART in combina-
tion with established NET biomarkers may facilitate the
monitoring andmanagement of patients withNETs, partic-
ularlythosewithPCC/PGLandpancreaticNETs.Long-term
longitudinal studies arenowneeded to fully establish the role
of CART as a marker for NET progression and prognosis.
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